Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you. Good morning and welcome to the BioArctic AB presentation for the third quarter of 2025. BioArctic is continuing in a great way in our new era, with yet another quarter where we see more and more patients getting access to Leqembi, and we are broadening our collaborations, utilizing our BrainTransporter technology. And we are also broadening our portfolio with new projects and new modalities. And we will talk more about that in today's presentation. Next slide please. Biotech is listed on the Nasdaq Stockholm Large Cap. And this is our disclaimer. Next slide please. I am Gunilla Osswald, and I'm the CEO of BioArctic. And I will share today's presentation with our CFO Anders Martin-Löf and our Chief R&D Officer Johanna Fälting. And our Chief Commercial Officer Anna-Kaija Grönblad. Next slide please. So I will start our presentation today by giving some key highlights. We go to next slide please. So before I get into this quarter and the presentation, I just want to give a high-level introduction to BioArctic AB. If we have any new listeners today. BioArctic AB is among the world-leading innovators in precision neurology. And we have two key platforms. The first platform focuses on the innovation, generation, and development of highly selective antibodies targeting aggregated, misfolded forms of toxic proteins. Examples here include, for instance, Lecanemab, Leqembi, and Exidavnemab. The second one involves utilizing our BrainTransporter platform in innovative ways to deliver antibodies and different modalities more effectively into the brain. In today's presentation, we will talk about both selective antibodies like Leqembi, Exidavnemab, and our new project for Huntington’s disease with Huntingtin, as well as our BrainTransporter technology, which we have utilized now for all our internal targets. And we have also started to use it for external projects. And we now have three different partnerships utilizing the BrainTransporter technology, including the recently signed deal with Novartis. Next slide please. During the second quarter this year, we held our first Capital Markets Day, where we presented our ambitions for 2030. And I'm really pleased to say that we are already delivering on our ambitions. So if we start with the first one, Leqembi is to be an established treatment in Alzheimer's disease. I'm really happy to see how Leqembi demand continues to grow. The second one is to have a balanced and broader pipeline with projects in all stages of development, and our pipeline is already broader and continues to increase and develop. The third one is additional successful global partnerships. Of course, we are very happy with the new collaboration with Novartis, and we have more positive discussions ongoing. The fourth one is our aim to be profitable and to have recurring dividends in the future. And we expect to be highly profitable this year. As we move to the next slide, please. As I said, we are already delivering on our ambitions. And now I will go through a bit about how we started with Leqembi. I think now we are well on our way to establishing Leqembi as a treatment for Alzheimer's disease, which is a disease-modifying treatment affecting the underlying condition. Thanks to our partner Eisai and their great work with Leqembi, it's now approved in 51 countries around the world, with Canada being the latest one. The iClick, the subcutaneous autoinjector, is referred to as a subcutaneous pen. Iclick was approved for maintenance dosing in the US during the quarter, and Eisai has already initiated a rolling submission for initiation dosing as well. And the next thing I want to mention is about Europe, where the launch has been initiated in Germany and Austria, and we're really happy to see that Finland has treated the first patients in a private clinic. Of course, this is great news for us from a Nordic perspective, since we are preparing for launch together with Eisai in the Nordic countries, and Anna will come back and talk more about this. And then there have been several presentations on Leqembi during the period and after the period. These presentations have demonstrated that long-term data over four years of treatment show continued increasing benefits over time, which is also really reassuring when following real-world data from Leqembi's use in clinical practice. And we have heard presentations from the US, Japan, and China, and the data have shown that the benefit and safety profile are at least in line with the Phase 3 results, which I think is great and encouraging. Subcutaneous administration data has also started to be presented. Then I also want to mention that, of course, we follow with great interest the fantastic progress with the blood-based biomarkers. And the guidance was launched earlier during the quarter about how to utilize the blood-based biomarkers. They can now be used both for confirmation and for charting. And we'll come back to that if we then look at the second part of the pipeline, which is progressing really well and growing with new projects. And I'm also really happy to be able to communicate that. We're also now working on another misfolded protein target called Huntingtin for Huntington's disease. Here we are working with antibodies, but we are also broadening into other modalities by utilizing our BrainTransporter technology. And Johanna will talk more about this in today's call. The third priority is to establish additional successful global partnerships. As I mentioned, we are very pleased with the new collaboration with Novartis concerning an undisclosed target for neurodegenerative diseases. And we will re-engineer that antibody to include our BrainTransporter technology, enabling better penetration into the brain. I also want to mention the other BrainTransporter collaborations that we have so far, including one with Eisai on BAN2401, where we're generating great data and another with BAN2403, for which we are now completing the tech transfer to Bristol Myers Squibb. It's also great to see that we have continued strong interest in our projects and our BrainTransporter technology for antibodies as well as for other modalities. The fourth part about the financials is that we have strong financials, and we are highly profitable this year with increasing royalties, as well as several milestones from Eisai and upfront payments from Bristol Myers Squibb and Novartis. Next slide please. If we think about the Alzheimer's field, it's evolving in a very promising way, and I want to highlight five different areas. The first one is that we see that we are getting easier and easier diagnosis by blood-based biomarkers, and I think this is important in helping to build the market in a simpler way and to help get the right patients to come to specialists to have a treatment initiated. The first tests are now available as confirmatory for specialists, as well as for triaging for primary care. If we then look at the second one, we see more and more data showing that earlier initiation of treatment with Leqembi shows a better effect. So when we're looking at the earlier patients in the Phase 3 Clarity AD open-label extension study, where now 48 months of data are available, we see that the majority of Lecanemab-treated patients were stable or even improved after 48 months of treatment. I think this is very encouraging, and I believe it also further supports the ongoing AHEAD 345 study in presymptomatic individuals with amyloid pathology, but without symptoms. The third one is also really important; the data being presented shows the importance of maintenance treatment to sustain retreatment and the benefit of continued treatment, which can continue even after the plaques are cleared, in order to clear the toxic protofibrils. And that's possible due to the mechanism of action and the low immunogenicity that we see with Leqembi. The fourth one is about more convenient dosing with Leqembi. Click the subcutaneous autoinjector. And I think this is a really important next step for Leqembi. And it's making the dosing process much easier for patients and their care partners to manage at home. We are also pleased to note that it was awarded as one of the top innovations for 2025 by Time Magazine. And the fifth one is that in the future, we expect to see more combination treatments for even better outcomes, and there is currently an ongoing study with Lecanemab and Eisai's tau antibody. And I think in the future we will see more and more combination treatments. So to summarize, the key is to identify patients at an early stage. And here we can use the blood-based biomarkers. And we can start Leqembi treatment early and continue treatment with convenient dosing using the Leqembi Click. So great progress in this field for Leqembi. Next slide please. So now we come to the R&D update and I hand over to our Chief R&D Officer, Johanna Fälting.
Thank you so much, Gunilla. Next slide please. So as Gunilla mentioned, BioArctic is among the world's leading innovators in precision neurology, where we have two key platforms: the antibody platform with highly selective antibodies targeting aggregated forms of toxic proteins, and these are intended to treat severe neurodegenerative diseases with high unmet medical need, such as Leqembi in Alzheimer's disease. Exidavnemab in Synucleinopathies, Parkinson's disease, or multiple system atrophy (MSA), and also the TDP-43 project for ALS. BioArctic AB is also developing a BrainTransporter technology that facilitates the passage of antibodies and other drugs across the blood-brain barrier. In addition, we are further developing our BrainTransporter technology and expanding it into new modalities beyond antibodies, such as enzyme proteins and even genetic medicines. Next slide please. So this is an overview of our R&D portfolio with the two platform antibodies and BrainTransporter and the cross-program synergies. The portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies, innovative in-house projects, and technology platforms with significant market and out-licensing potential. So far, our BrainTransporter platform has generated three collaborations with Eisai, Bristol Myers Squibb, and Novartis, and all of these collaborations are progressing really well, each focusing on different targets. But importantly, the BrainTransporter technology is owned by BioArctic AB and has the potential to generate more collaborations in the future. You will also note a new BrainTransporter project in the portfolio, the HD 4801 for Huntington’s disease, and I will come back to this specific project later in the presentation. To summarize, we are both advancing and broadening our R&D portfolio with new projects into new disease areas and with new collaborations. Next slide please. So Exidavnemab is an antibody that selectively targets the pathological alpha synuclein aggregates while sparing the physiological monomers and is currently in Phase II. A study testing the safety and tolerability of Exidavnemab. In this study, we are also exploring a wide range of biomarkers, both biochemical and digital, and we have a quite unique approach in including the right patients in the study with the smell test, which is an early sign of Parkinson's if you have an impaired sense of smell and also a CSF seeding amplification test to ensure that we have correctly diagnosed patients with the alpha-synuclein pathology. In this study, the high dose cohort is currently ongoing both in Parkinson's and multiple system atrophy, and the results are expected mid-2026. So following this study, there are several potential possibilities for future development in different synucleinopathies such as Parkinson's disease, multiple system atrophy (MSA), and dementia with Lewy bodies (DLB), and we are currently preparing for the next stage of development. Next slide please. It's very exciting that we are now expanding our portfolio into a new neurodegenerative disease, Huntington's disease. And this is an inherited progressive neurological and neuropsychiatric disorder caused by impaired function and degradation of nerve cells in specific areas of the brain. Huntington's disease is caused by a toxic mutant huntingtin protein in the brain, and the mutations in this gene result in a buildup of toxic, aggregated huntingtin protein causing Huntington's disease. The disease onset is typically between 30 and 50 years of age, and it is fatal within 10 to 30 years. Current treatments are only symptomatic, and there is a large unmet medical need for better treatments. So next slide please. Targeting the huntingtin protein in Huntington's disease is an excellent strategic fit into our portfolio at BioArctic AB and aligns with our capabilities. So this project is built on BioArctic AB's extensive experience in developing antibodies against misfolded, aggregated toxic proteins, and also our BrainTransporter platform that will enable us to increase the brain delivery of the drug. In this project, several modalities are being explored in parallel, such as antibodies and genetic medicine approaches. And since this is a brain target, we have of course also combined it with our BrainTransporter technology. So we are excited that we now expand our portfolio with yet another neurodegenerative disease in addition to Alzheimer's, α-synuclein disorders, ALS, and galactosemia, with the potential to bring hope for even more patients. Next slide please. So with that, I will hand over to our Chief Commercial Officer, Anna-Kaija Grönblad, for a commercial update.
Thank you, Johanna. And we can go to the next slide please. And I will go back to Leqembi again. And I'll start with the regulatory update for all of you. Since the last quarterly report, Leqembi IV has now been approved in three additional countries: India, Australia, and at the end of October, Canada. So in total, it is approved in 51 countries and territories. And as of October, in addition to the US, the IV maintenance treatment, meaning once every four weeks, is also approved in China. In Qatar, the United Arab Emirates, and India. Anders will soon present the sales numbers. In short, I would say that Leqembi's growth continues steadily. So in Q3 versus Q2, when you adjust for China's actual demand, the growth was 14%. And we have seen recent launches in Mexico and Saudi Arabia. And as of August and September, as I mentioned, Leqembi was also launched in the EU, in Austria, and Germany where patients have started treatment. So, what we hear is that within the first two months, around 350 centers were registered in the system for the controlled access program. And as educational activities are being rolled out in the two countries, registrations and prescriptions continue to increase at major specialist clinics. And finally, in the Nordics, of course, as mentioned, there is a private clinic in Finland offering Leqembi treatment to patients willing to pay out of pocket. And we know that a few patients have received treatment in October. So this is an important milestone for us in our ambition to also become a fully-fledged pharmaceutical company. In the meantime, the price and reimbursement dialogue continues with all the Nordic countries, and we aim to launch gradually throughout 2026. So next slide please. So, additionally, I would like to spend a few minutes again on the Leqembi Click, the subcutaneous autoinjector, which was approved in the US in August and launched as of early October. As Alzheimer's disease is a progressive condition where neurodegeneration and cognitive decline continue even after plaque removal, it is important to offer both healthcare professionals and patients the choice between continuing with once-monthly infusions in hospitals or switching to once-weekly at-home injections after the 18-month treatment. So this obviously could be a benefit for the patient, who might want to travel and feel less bound to the hospital, but also to healthcare providers in reducing the resources related to the infusions. Reimbursement for the click is expected to be included on formulary at the beginning of 2027, but individuals can seek insurance coverage via the medical exemption process, which is something that is quite common in the US. This is truly a major step in the treatment of Alzheimer's disease patients. And recently, Leqembi was selected by Time as one of the best inventions in the medical and healthcare category. In addition, Eisai has a role in the supplemental Biologics License Application (sBLA) ongoing for the weekly initiation treatment in the US since September, which is planned to be completed in the last quarter of this year. So potential approval may occur in Q2 or Q3 next year. And finally, submissions for the subcutaneous weekly initiation treatment are also planned for Japan before the end of this year. Next slide please. So moving on to my final slide. And this is to highlight again the true advancements we are seeing with Leqembi and the parallel development in the usage of diagnostic blood tests. If you remember, US clinical guidelines were presented at the AD/PD Congress in July this summer, stating that blood-based biomarker tests showing more than 90% sensitivity and specificity can be used for confirmatory diagnosis in patients with cognitive impairment. Meanwhile, the Roche Phosphotau 181 blood test was granted IVD clearance from the FDA for use as a triage test in primary care. So more tests will be conducted. 350,000 tests are expected to be used in 2025, and a new CMS payment rate is coming up from January next year. And of course, as more patients are being tested, more patients will receive a diagnosis. So as we see, these advancements will contribute significantly to the growth of Leqembi going forward, especially in the US, China, and Japan. So that's all from me. And with that, I will now hand over to our CFO, Anders Martin-Löf.
Thank you, Anna. If we start to look at the Leqembi numbers, the global Q3 sales came in at ¥18 billion, or roughly $121 million. At first glance, that looks quite negative, as there was a 22% decrease from the second quarter of 2025. But that is all due to a large stockpiling effect in China in the second quarter. So, as I calculated what the growth would have been from the second to the third quarter without the stockpiling effect, the growth would have been 14%. We recorded a royalty of 117.2 million Swedish. That's also then down from 162.5 million Swedish in the second quarter. But we have also estimated what the royalty would have been without the stockpiling effect. And then we would have been around 125 million Swedish in the second quarter and 135 in this quarter. So I think that's a better reflection of the actual development of the Leqembi sales worldwide. Turning then to China. So actual recorded sales were ¥8.2 billion, or approximately $0.6 million. So, a 97% decrease from the second quarter. Basically, the clinics in China are receiving Leqembi from inventory right now. In the third quarter, the actual demand was roughly $18 million, and that's a 10% increase from $16 million in the second quarter. But all in all, this means that there is still quite a significant inventory left in China, so we expect very low sales in China. Also during the fourth quarter. And that was also reported by Eisai. Turning to the US, the sales are increasing. Well, they were up to ¥10.2 billion, or roughly $69 million, representing a 12% increase from the second quarter. And here Eisai is really trying to leverage the developments that were being discussed with the blood-based biomarkers that are now being used more and more, and the acceptance of Leqembi for maintenance therapy this year and for induction next year. But to really get the full effect of this, you have to target the primary care practitioners. So that is what Eisai is doing now. They're targeting roughly 3,500 primary care practitioners. They're running significant educational programs and conducting large awareness campaigns directly aimed at the patients. So they're really building momentum now to start seeing an impact from IT and blood-based biomarkers, probably starting more from next year. But they're really starting to do the groundwork now. And here you can say that they're mimicking Japan a little bit. Japan is the market that has come the furthest along in the demand expansion phase. Sales here were $42 million, representing a 13% increase from the second quarter. And here they have really succeeded in setting up a good treatment chain, where roughly 4,200 doctors are referring to 800 initial treatment centers. And there, the patients stay for a while, and then they are moved over to follow-up facilities. So that's a system that has worked incredibly well, and that is what they're trying to achieve now in the US as well. I think it's also really interesting to see that the disease awareness campaigns they're running for mild cognitive impairment in Japan are significantly increasing the recognition rates because we all know that mild cognitive impairment, which is the earliest phase of the disease, is really where you want to treat the patients with a disease-modifying therapy. You can have the most effect if you start as early as possible, but today those patients aren't really being diagnosed to a large extent. So. These awareness campaigns can truly start to build momentum for more patients receiving the drug when they genuinely should have it. And then, as I mentioned, the EU launch has been initiated in Austria and Germany. It's really exciting to see that this is starting well. However, it will take some time before we see any significant impact in our royalties from the EU, which is a slightly slower market than the US and Japan. If you then turn to the Leqembi global sales forecast, they have a forecast of ¥76.5 billion for their fiscal year 2025 for Leqembi. And if you look on the right-hand side of the graph, you can see that they have already, in the first two quarters of that fiscal year, achieved 48% of the forecast in the US, 49% in Japan, and already 83% in China. So all in all, if you also include the other countries, they have achieved roughly 52% of the overall annual forecast in the first two quarters of that period. And since they are growing, we have very high confidence that they will reach the forecast for the year. So everything is looking really, really good for Leqembi. And it seems they are on track to reach their forecasts with some margin. If we then turn to our own numbers, you see that the Q3 net revenues were 133 million. And this quarter, it was mainly based on the recurring revenues, with royalties of 117 million and co-promotion revenues of 5 million. It's exciting to see that we're becoming more and more like a typical company with recurring revenues that make up a larger share of our revenue base. We also recorded some revenues from the new Novartis agreement. Uh, as you know, we received a $30 million upfront payment when we started that collaboration, and now we have recorded $9 million of that in the third quarter, with plans to record the rest during the remainder of that collaboration. Looking at our operating expenses, they increased to 150 million this quarter compared to 95 million a year ago. This time around, that was basically just normal cost. We have had large currency effects in the previous two quarters, but not this quarter. So the underlying operating costs were 146 million. And that's slightly over our recurring revenues. So we have operating costs that are 24 million higher than our recurring revenues, but we are approaching a point where our recurring revenues will exceed our operating expenses. So we are getting closer and closer to long-term profitability. If you then look at our costs for the remainder of the year, we expect them to keep increasing since we have a more mature project portfolio and we have built up our commercial organization. I have previously stated that I expect our full-year costs to be roughly 50 to 70% higher than those of last year. Now we think we will be in the lower range of that interval. So I would say roughly 50 to 60% higher than the cost of last year. And then on the right-hand side, you see that the operating loss was 29 million for the third quarter. We expect something similar in the fourth quarter. So the operating profit for the year should be well above 1 billion Swedish. On the next slide, you can see our net result on the left. It's then, of course, a bigger loss than the operating loss, and that's mainly explained by the accrued taxes of 65 million. But we also have a positive financial net of 8 million. So that mitigates the issue somewhat. And then the operating cash flow, you typically see one very big bar. And that's the payment of the $100 million upfront payment that we received from Bristol Myers Squibb in the second quarter. The $30 million upfront payment from Novartis had not been received in the third quarter. It was received in October. So the bar you see on the left-hand side, with our cash balance right now of 1.9 billion Swedish, does not include the Novartis payments. So our financial position will continue to be strengthened in the fourth quarter. So we are going to end the year with a very, very solid position. I think that was all from me. And now I hand back to Gunilla for some closing remarks.
Thank you so much, Anders. So we are coming towards the end of today's presentation with some upcoming news and some closing remarks. So next slide please. So we are now in the fourth quarter of 2025. And I think it's great to see that more and more patients are getting access to Leqembi around the globe. I'm also really pleased to see that we're starting, even if it's small. So we're starting in the Nordics. We see continued regulatory processes on Lecanemab with the Canada approval, and I think it's great to see Leqembi being approved for maintenance dosing in the US. And our partner Eisai is working hard to conclude the supplementary BLA filing for Leqembi in the US for the initiation dose, and also to file in Japan for both initiation and maintenance dosing. We are, of course, looking forward to the next Alzheimer Congress. It's CTAD in San Diego at the beginning of December, where we'll note several presentations on Lecanemab, including subcutaneous data and more real-world evidence data from, for example, the U.S. registry. So this is something I'm really looking forward to. So please proceed to the next slide. So the key takeaway from today's presentation is that BioArctic is now in a new era. And we see great progress both on Leqembi as well as the rest of our portfolio and the BrainTransporter technology. We have already started to deliver on our 2030 ambitions. Leqembi is well on track to become an established treatment for Alzheimer's disease. Sales continue to show increasing demand on a global level. Further regulatory approvals, subsequent launches, and reassuring data from long-term treatment and real-world evidence. Our portfolio has expanded, and we have started programs for Huntington's disease using different modalities. Our business development efforts continue to deliver, with a third BrainTransporter collaboration now having been initiated during the third quarter. And this was the first of its kind. And it shows that we are also expanding to become a platform company. And the last point is that we have strong financials as described, with great cash flow, milestones, and record royalties growing more than 180% year on year. So I think the future looks very bright for BioArctic and it's bringing hope for many patients. Next slide please. So with that, we say thank you so much for your attention. And we're happy to take some questions.
If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the Pound Key on your telephone keypad. The next question comes from Joseph Hedden from WR Securities. Please go ahead.
Good morning. Thanks for taking my questions. Firstly, regarding Leqembi, do you have any visibility on when regulatory filings might be made in Europe or China, or what the strategy there is? And then secondly, it's great to see a Huntington project focusing on the BrainTransporter technology. I know that the first program is an antibody, and you've mentioned genetic medicines. Is BrainTransporter capable of, for instance, using an AAV vector? I mean, the unique therapy for Huntington's disease has made a lot of noise recently. Does any significant modification need to happen with your current platform to be able to carry a vector, such as AAV? Firstly, on the Leqembi, do you have any visibility on when regulatory filings might be made in Europe or China, or what the strategy is there?
Thank you so much, Joseph. Excellent questions. I think the first question is regarding Leqembi in Europe and China. We cannot comment on that. I mean, right now, we are really happy about the progress in the US and Japan. We know our partner is doing everything they can to help as many patients as possible around the world. So, we'll come back to that. Then, regarding your question on Huntington's disease, we are also really happy to see progress with the BrainTransporter. I didn't understand any specific question. I understand.
I think I can.
If I may just. And then I hand over to you, Johanna. And then for the BrainTransporter, I think it's really, really good to see that we can utilize it for several different modalities and definitely help in getting different modalities better into the brain. And I think it's important to point out that BrainTransporter is not one single entity. It's a platform with many different tailor-made ways to handle various targets and modalities. So we have several different approaches that we utilize depending on whether it's an extracellular target, an intracellular target, or what kind of modality we have. And then hand over to Johanna who understands the question I missed.
Yes. Thank you so much, Joseph, for that. Excellent question. And we are, of course, closely following the competitive landscape. And we understand, and we have seen the UniQure data. I think it's excellent data, but that's a treatment that is not for everyone. It's quite an invasive treatment, and you might actually need around a 15-hour surgery for one patient to administer that drug. And it's done with intrathecal administration and injections at different sites in the brain currently. So our approach is a bit different, and I can't speak too much about it today before we have the patents in place. And so, we have another approach, and we are not primarily targeting AAV with our BrainTransporter technology.
I think it's excellent data, but that's a treatment that is not for everyone. Thank you very much.
I hope that answered your question. Thank you, Johanna.
I think it's excellent data, but that's a treatment that is not for everyone. I think it's excellent data, but that's a treatment that is not for everyone.
The next question comes from Susanna Quickborn from Handelsbanken. Please go ahead.
Hello. I'd like to ask a question regarding Leqembi sub-q. Listening to the Eisai conference call. They talked about Leqembi being listed in formularies only by 2027. There seems to be a medical exemption program which would address something like 80% of patients. To me, it sounds like there's likely to be more paperwork associated with that. It sounded like access was going to be limited at least until 2027. Maybe you can just sort of explain that to me. And then also, how does that impact your competitive advantage versus Eli Lilly's fromTonit.gh, which is also expected to read out data in 2026. And they have the subcutaneous formulation as well.
Yeah. So we start with your question on click. And the process in the US with the reimbursement agency, CMS, is that there are certain times of the year when you need to submit in order to be included in the next year. That's why we expect Leqembi by Eisai to be on the formulary starting January 2027. Right now, just as you said, Susana, there is a possibility to utilize the medical exemption program, which I think many of these physicians are used to doing for other treatments. And what we have understood from Eisai is that it's not overwhelming paperwork. It's a fairly easy process that can help most patients to already be reimbursed right now. And I'll also go on the differentiation part a little bit and then hand over to Anna. So I think we see the Eclipse as a really good differentiator compared to competitors. We will follow with great interest when additional efficacy data becomes available. We haven't seen much yet. So I think each compound has to demonstrate its efficacy before we can comment too much. And we haven't seen much of it yet. So meanwhile, I think we're really happy with Leqembi, as all the data we have seen so far looks really, really promising. And more data is expected to be shown at CTAD. So I don't know if you want to add something.
No, not really. I think again, we haven't seen that much data on it yet. So. So I think it's too early to say anything about it, but we, of course, understand that they also see the need for a subcutaneous auto-injector. We think that this will be a key driver for patients receiving an easier treatment. So we see that. Eli Lilly also recognizes this need and sees us as well. This is a competitive advantage.
If I could have a follow-up question. I also saw that Takeda discontinued their α-synuclein antibody, which they reported having phase two results on. Maybe you can talk about the differentiation of your α-synuclein antibody.
And, I'll also go on the differentiation part a little bit and then hand over to Anna. I think it's really important to understand that every antibody is different from the others. And we think that we have a clearly superior antibody, much more selective, the most selective antibody that we know for α-synuclein, between the pathological forms and the physiological forms. So we have more than 100,000-fold selectivity, which is a huge difference from competitors. And also, I think it's important to see the design of the clinical studies as we believe we are designing better studies for the future. But I will hand over to Johanna.
And I'll also go on the differentiation part a little bit and then hand over to Anna. I completely agree, and thank you for the question. Of course, it's always sad when a clinical study that brings hope to a patient does not yield results. But I think that we have a differentiated profile, both in terms of the selectivity for what we believe are the toxic species, the aggregated species, and the very high affinity for those species. We also have a superior human PK profile compared to the AstraZeneca and Takeda studies that recently reported results. It was also a fairly small, I would say, Phase Two clinical trial. And I think that we can have a clear differentiation with this, both in terms of human PK study design and selectivity for the toxic species.
So, not much read-over, I would say.
Absolutely not.
Okay. It was also fairly small, I would say, a phase two clinical trial.
The next question comes from Natalia Webster from RBC. Please go ahead.
Hi there. Thanks for taking my questions. Firstly, I was wondering about your Leqembi guidance up to March. This is implying a slowdown in growth for Leqembi sales for calendar Q4 into Q1 26. So I'm just curious to hear if you think this is conservative, appreciating that there may be some further impact from the China inventory adjustment in Q4. And then my second question is on the European launch. Appreciate it's early days and it could take some time to see a more meaningful contribution here, but are you able to provide a bit more feedback on how this is progressing? And if you're encountering any of the initial challenges that you saw in the US around capacity or otherwise? And then finally, just on profit, you've maintained your long-term ambition for sustainable profitability. I was wondering if you're able to touch on any key considerations for cost phasing in 2026, and if you are able to confirm that you still expect to reach sustainable profitability from 2026 as well. It was also fairly small, I would say, Phase II clinical trial.
So I think it's related to this. You should start on this question, right.
So, if you look at the forecast, I think you're specifically asking whether they will be applicable to China. Well, all in all, they are already at 52% of the full-year forecast after two quarters, and 87% in China. I think it's correct that the Chinese sales will be very low in the next quarter as well. But then I think, more or less, the inventory should be used up. So, they should have a strong first quarter next year. So, we remain very confident that they will reach their forecast for the full year. And so are they. That's what they communicated on their call. As for the profit for next year, we will not comment on our costs for next year until we finish the year. So you'll hear more about that in February when we communicate our year-end results.
And then there was a question for.
Yes, regarding the EU launches. And what I can say is that, of course, the EU consists of 27 countries, and all of these countries have their national market access processes on price and reimbursement. So I would say that after Germany and Austria, typically being the early launch countries, it takes quite some more time before each country has gone through this process. So, I would say that we should be cautious when it comes to the sales coming from Europe next year. I think we are, let's say, infrastructure-wise, in a better situation in the USA than in the EU. But still, I mean, this is a new treatment paradigm that is being implemented. So each clinic has to systematically go through and have a checklist on what needs to be in place to start the treatments on patients. So I think we should be kind of cautious and understanding of the changes that need to be in place in the clinic. So, it will be rolled out gradually throughout Europe next year.
And I just want to remind you that we've always said Europe is a small proportion of the global sales. So you'll hear more about that in February when we communicate our year-end results. Especially, I mean, the coming two years, but also long term. It's really the US, Japan, China, and other parts of Asia and the world that also contribute. So you'll hear more about that in February when we communicate our year-end results. A lot.
So you'll hear more about that in February when we communicate our year-end results. So you'll hear more about that in February when we communicate our year-end results.
The next question comes from Viktor Sundberg from Nordea. Please go ahead.
So you'll hear more about that in February when we communicate our year-end results. Hi. Thanks for taking my question. So, one first on financials. So I just wondered how we should think about the Novartis upfront payment being recognized over 21 months. Will this be in a linear fashion, or how should we think about the revenue contribution of that part going forward? So you'll hear more about that in February when we communicate our year-end results.
Short answer is yes.
Yes, it will be in a linear fashion.
So, yes. Linear. Okay. It's very hard to do. We are delivering, as we have communicated, we are working on a Novartis compound that we are modifying, and we will deliver it back to them. And that will take some time. And it's really hard to estimate how large a share of that work has been done. So you typically do that in a linear fashion over the expected time course of the collaboration. So linear.
Okay. Thank you. And also, I had a question on your competitive position or competitive position versus, you know, looking at the curve, it seems that they are accelerating sales. I guess Eisai has done a lot of the groundwork already to prepare for that. But I just wondered about your discussions with Eisai, like, why? Why are some patients choosing Kisunla over Leqembi, or why are some patients choosing Leqembi over Kisunla? What's your feedback here? So far in the launch. Thank you.
Would you like to take it?
Yes. I mean, of course, we're still the number one disease-modifying treatment for Alzheimer's in the US as well. But as you say, I mean, of course, Kisunla is having some advantages, us being a frontrunner in establishing these kinds of treatments on the market. But what we can see is that Eisai reports it's not reducing the Leqembi market, but rather growing the total market as such. Of course. I mean, there is a difference in that they have once-monthly dosing today, and we have twice-monthly dosing during the 18-month treatment phase. And then you can choose to go to once monthly or bi-weekly. So, of course, every patient is an individual and has to decide what works best for them. But otherwise, I think Leqembi is still showing strong growth. So. And in total, it's growing the overall market.
Okay. Thank you very much.
The next question comes from Sebastian van der Schoot from Kempen. Please go ahead.
Hi Tim, congratulations on the progress and thank you for taking my question. It's just one from our side. Could you maybe give some insight into what would determine your go or no-go decision? Decision for further development of the Parkinson's program. What type of signals do you want to see against placebo? Push the development forward. And what could the next steps for the program look like? Thank you.
Yes, absolutely. So I will start and just say that Exidavnemab, which is currently in a phase two study, and the main task for this study is to look at safety and tolerability. And we have two doses. We first had a lower dose where we conducted a safety review that supported us in progressing to the higher dose stage exactly as we had planned and wanted. And then we have also branded it not only for Parkinson's disease but also for multiple system atrophy, where we have received Orphan Drug Designation. So I think, I mean, we are conducting a lot of biomarker studies. But that's really in order to prepare also for the next step, for phase two B. So I think it's really important to understand that the expectation here is truly to assess safety and tolerability for this program. And so far, what we have seen looks really good. We expect the readout to occur just after summer next year. The study is ongoing and still recruiting, so it's a little hard to say exactly when it will happen, but the best estimate is a little bit after summer next year. And then there are a lot of opportunities for this asset. As we have described before, it can be Parkinson's disease dementia, it can be Lewy body dementia, and it can be other different parts of Parkinson's disease. It can be MSA. So there are a lot of opportunities. And at the moment we are evaluating different kinds of those indications and preparing for the next step. So I think this is a very interesting asset, very exciting with a lot of opportunities. I don't know if you want to add something, Johanna.
No, I have nothing to add to that. Just to say, I'd like to echo what Gunilla said, this is quite a small study and a short study, so not too much should be expected in terms of biomarker readouts. It's a safety and tolerability study, it's three months, and that's a bit too short to see efficacy on biomarkers related to disease modification.
That should be the next step. Okay.
Got it. Thank you, everyone.
No, I have nothing to add to that.
As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad.
So there doesn't seem to be any people in the phone queue right now. But we have some written questions that have been posted during the call, so I'll read them out loud. And then Gunilla can direct who should take the question, although I think the first one might be for Anders, but it's from Peter who wonders, looking forward when we start to record sales for Leqembi in the Nordic countries, how are we going to report that going forward?
So, in our profit and loss statement. You have our total revenues. And then in the notes, we will have our different revenue split up by line. And we already do, actually. So, the revenues from the Nordics won't be seen. Straight away. They are part of what is called co-promotion revenue, which is the reimbursement we get from Eisai for profit sharing. But over time, yes, I think we will comment on how things are going in the Nordics. I hope that answers the question.
Thank you. And then follow-up question from Peter as well regarding opex and the difference in opex. If you compare Q1 and Q2, costs are down in Q3. And he wonders what were the reasons for this and then going forward? Also, what level can we expect? Is there anything you can say about that right now?
So, our costs are quite variable. So if you deduct the other operating expenses, which are mostly currency-related. Yes, our costs were down a little bit in the third quarter, but we expect them to go up again in the fourth quarter and then we'll see what happens next year, But it's too early to tell exactly what that will look like. But of course, with a maturing R&D portfolio, you incur larger costs, which is a great thing for a company like ours.
Thank you. Then we had a question for Frederic, but I think we answered that because it came from somebody else as well. And then Eric from Carnegie has a question regarding the evoke trials that are coming up soon in just the next couple of weeks. The expectations on the results for the Evoke trial, where semaglutide is tested in early Alzheimer's disease, and for Evoke and Evoke Plus, what are our thoughts on that? If that study is positive, how could that potentially impact or not impact the treatment? Leqembi.
Yeah. I am really looking forward to seeing the results, and it's quite imminent now. I think it's too well designed. The clinical trials in phase three did not have a proper phase two. So it's very hard to say anything about what to expect here, I think. If positive, then I think it's a complement to Leqembi. I don't see this as a competitive treatment. I see it as a complementary treatment because it has a completely different mechanism of action and potentially could help patients together with Leqembi.
But of course, with a maturing R&D portfolio, you incur larger costs, which is a great thing for a company like ours. Thank you. I think the last one regarding the risk involving China. You mentioned it earlier, but perhaps you could clarify once more our perspective on the stocking effect in China, how long it's expected to last, and when we might anticipate a rise in new sales within China.
But of course, with a maturing R&D portfolio, you incur larger costs, which is a great thing for a company like ours. So the stockpile that was built up in Q2 is expected to run out during the fourth quarter. So you should see an effect of that on the sales in the fourth quarter, but not beyond that. That would be my estimate. Yeah.
Thank you. Those were all the questions in the queue. I don't believe, operator, that we have any more questions waiting in line either. And if so, I think that concludes today's call. Today's call. Thank you so much for listening. And we'll see you back in a quarter from now. Thank you so much.
Thank you. Have a good day.



















